The Post welcomes letters up to 250 words on topics of general interest. Letters must include full name, home address, day and evening phone numbers, and may be edited for length, grammar and ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

In its latest filing court filings, the law firm that is appealing last year’s $600 million settlement between residents and Norfolk Southern to remedy damages accused by the 2023 train derailment ...